placeholder
and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Document type
Language
Year
  • 1
    Language: English
    In: Journal of allergy and clinical immunology, 2013, Vol.132 (2), p.353-360.e2
    Description: Background Subcutaneous allergen immunotherapy (SCIT) and sublingual allergen immunotherapy (SLIT) are safe and effective treatments of allergic rhinitis, but high levels of compliance and persistence are crucial to achieving the desired clinical effects. Objective Our objective was to assess levels and predictors of compliance and persistence among grass pollen, tree pollen, and house dust mite immunotherapy users in real life and to estimate the costs of premature discontinuation. Methods We performed a retrospective analysis of a community pharmacy database from The Netherlands containing data from 6486 patients starting immunotherapy for 1 or more of the allergens of interest between 1994 and 2009. Two thousand seven hundred ninety-six patients received SCIT, and 3690 received SLIT. Time to treatment discontinuation was analyzed and included Cox proportional hazard models with time-dependent covariates, where appropriate. Results Overall, only 18% of users reached the minimally required duration of treatment of 3 years (SCIT, 23%; SLIT, 7%). Median durations for SCIT and SLIT users were 1.7 and 0.6 years, respectively ( P  〈 .001). Other independent predictors of premature discontinuation were prescriber, with patients of general practitioners demonstrating longer persistence than those of allergologists and other medical specialists; single-allergen immunotherapy, lower socioeconomic status; and younger age. Of the persistent patients, 56% were never late in picking up their medication from the pharmacy. Direct medication costs per nonpersistent patient discontinuing in the third year of treatment were €3800, an amount that was largely misspent. Conclusion Real-life persistence is better in SCIT users than in SLIT users, although it is low overall. There is an urgent need for further identification of potential barriers and measures that will enhance persistence and compliance.
    Subject(s): Abridged Index Medicus ; adherence ; Administration, Sublingual ; Adult ; Allergens ; Allergens - administration & dosage ; Allergens - immunology ; Allergic reaction ; Allergic rhinitis ; Allergy ; Allergy and Immunology ; Animals ; Biological and medical sciences ; compliance ; cost ; Desensitization, Immunologic - economics ; Desensitization, Immunologic - methods ; Desensitization, Immunologic - psychology ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunotherapy ; Injections, Subcutaneous ; Male ; Medical sciences ; Middle Aged ; Netherlands ; Patient Compliance - psychology ; Patient Compliance - statistics & numerical data ; persistence ; Poaceae - immunology ; Pollen - immunology ; Pyroglyphidae ; Retrospective Studies ; Rhinitis, Allergic ; Rhinitis, Allergic, Perennial - etiology ; Rhinitis, Allergic, Perennial - therapy ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; specific allergen immunotherapy ; subcutaneous ; subcutaneous allergen immunotherapy ; sublingual ; sublingual allergen immunotherapy ; Trees - immunology
    ISSN: 0091-6749
    E-ISSN: 1097-6825
    Source: Backfile Package - All of Back Files EBS [ALLOFBCKF]
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: Journal of clinical oncology, 2011-11-01, Vol.29 (31), p.4143-4150
    Description: PURPOSE: We studied cumulative incidence, risk factors, therapeutic strategies, and outcome of symptomatic osteonecrosis in pediatric patients with acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: Cumulative incidence of osteonecrosis was assessed prospectively in 694 patients treated with the dexamethasone-based Dutch Child Oncology Group-ALL9 protocol. Osteonecrosis was defined by development of symptoms (National Cancer Institute grade 2 to 4) during treatment or within 1 year after treatment discontinuation, confirmed by magnetic resonance imaging. We evaluated risk factors for osteonecrosis using logistic multivariate regression. To describe outcome, we reviewed clinical and radiologic information after antileukemic treatment 1 year or more after osteonecrosis diagnosis. RESULTS: Cumulative incidence of osteonecrosis at 3 years was 6.1%. After adjustment for treatment center, logistic multivariate regression identified age (odds ratio [OR], 1.47; P 〈 .01) and female sex (OR, 2.23; P = .04) as independent risk factors. Median age at diagnosis of ALL in patients with osteonecrosis was 13.5 years, compared with 4.7 years in those without. In 21 (55%) of 38 patients with osteonecrosis, chemotherapy was adjusted. Seven patients (18%) underwent surgery: five joint-preserving procedures and two total-hip arthroplasties. Clinical follow-up of 35 patients was evaluated; median follow-up was 4.9 years. In 14 patients (40%), symptoms completely resolved; 14 (40%) had symptoms interfering with function but not with activities of daily living (ADLs; grade 2); seven (20%) had symptoms interfering with ADLs (grade 3). In 24 patients, radiologic follow-up was available; in six (25%), lesions improved/disappeared; in 13 (54%), lesions remained stable; five (21%) had progressive lesions. CONCLUSION: Six percent of pediatric patients with ALL developed symptomatic osteonecrosis during or shortly after treatment. Older age and female sex were risk factors. After a median follow-up of 5 years, 60% of patients had persistent symptoms.
    Subject(s): Adolescent ; Age Factors ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Biological and medical sciences ; Child ; Child, Preschool ; Dexamethasone - administration & dosage ; Dexamethasone - adverse effects ; Diseases of the osteoarticular system ; Female ; Follow-Up Studies ; Humans ; Incidence ; Kaplan-Meier Estimate ; Logistic Models ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Multivariate Analysis ; Netherlands - epidemiology ; Odds Ratio ; Osteonecrosis - chemically induced ; Osteonecrosis - diagnosis ; Osteonecrosis - diagnostic imaging ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Prevalence ; Proportional Hazards Models ; Prospective Studies ; Radiography ; Risk Assessment ; Risk Factors ; Sex Factors ; Time Factors ; Treatment Failure ; Treatment Outcome ; Tumors ; Vascular bone diseases
    ISSN: 0732-183X
    E-ISSN: 1527-7755
    Source: Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: Pediatric pulmonology, 2013-08, Vol.48 (8), p.789-796
    Description: BACKGROUND: Invasive pulmonary aspergillosis (IPA) is a life-threatening complication in immunocompromised patients. Early diagnosis and therapy improves outcome. Assessment of galactomannan (GM) in bronchoalveolar lavage (BAL) fluid is a proposed tool to diagnose IPA. Little is known about the diagnostic value of BAL GM in children. MATERIALS AND METHODS: Retrospectively, 72 bronchoscopies were analyzed for GM in patients fulfilling the host factor criteria as defined by the EORTC/MSG. A cut-off index value GM of 〉/=0.5 was used. Clinical data, results of chest CT-scans and BAL cultures were collected. RESULTS: Sensitivity, specificity, PPV, and NPV of BAL GM for a diagnosis of proven and probable IPA (n = 41) were 82.4%, 87.5%, 82.4%, and 87.5% respectively. A significant relation was found for BAL GM and abnormal chest CT (P = 0.01). No significant relationship was observed between BAL Aspergillus sp. culture and chest CT (n = 47). BAL GM and serum GM correlated significantly. In 9 out of 12 patients classified as possible IPA, antifungal therapy was continued or started, despite a negative BAL GM. CONCLUSIONS: BAL GM test had good diagnostic value in children suspected of IPA. However, the decision to continue or start antifungal therapy was mainly determined by the clinical suspicion of IPA based on chest CT-outcome, serum GM index values and failure of antibiotic therapy.
    Subject(s): Adolescent ; aspergillosis ; Aspergillus - isolation & purification ; bronchoalveolar lavage ; Bronchoalveolar Lavage - methods ; Bronchoalveolar Lavage Fluid - microbiology ; Bronchoscopy ; Child ; Child, Preschool ; Children ; Cross infection ; Diagnosis ; Diagnosis, Differential ; Early Diagnosis ; Female ; Follow-Up Studies ; galactomannan ; Humans ; Infant ; Invasive Pulmonary Aspergillosis - diagnosis ; Invasive Pulmonary Aspergillosis - microbiology ; Juvenile offenders ; Male ; Mannans ; Nosocomial infections ; Pulmonary aspergillosis ; Reproducibility of Results ; Retrospective Studies
    ISSN: 8755-6863
    E-ISSN: 1099-0496
    Source: Hellenic Academic Libraries Link
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Language: English
    In: Journal of allergy and clinical immunology, 2007, Vol.119 (4), p.892-898
    Description: Background Sublingual immunotherapy (SLIT) is considered safer and more convenient than subcutaneous therapy and therefore has been proposed as especially suitable for children and in primary care. Most efficacy studies in children lack power to be conclusive, and all have been performed in referral centers. Objective To investigate the efficacy of SLIT with grass pollen allergen in children and adolescents with rhinoconjunctivitis in a primary care setting. Methods Youngsters aged 6-18 years with hay fever were enrolled from general practices and randomly assigned to receive placebo or grass pollen mix for 2 years. The primary outcome was the mean daily total symptom score (scale 0-15) comprising sneezing, itching nose, watery running nose, nasal blockage, and itching eyes during the months May-August of the second treatment year. Results Out of 204 youngsters randomized, 168 entered the intention-to-treat analysis (91 verum, 77 placebo). The mean daily total symptom score did not differ between participants allocated to verum and those allocated to placebo (difference for verum minus placebo: −0.08, 95%CI, −0.66-0.50; P = .78). No differences were found for rescue medication–free days, disease-specific quality of life, and overall evaluation of the treatment effect. Local side effects were more frequent in the verum group (39% vs 17% of participants; P = .001). Conclusion Sublingual immunotherapy with grass pollen in a primary care setting is not effective in children and adolescents. Clinical implications Currently, SLIT cannot be recommended for general practitioners as a therapeutic modality in youngsters with grass pollen allergy.
    Subject(s): Abridged Index Medicus ; Administration, Sublingual ; Adolescent ; Allergens - administration & dosage ; Allergens - immunology ; Allergens - therapeutic use ; allergic rhinitis ; Allergy and Immunology ; Analysis ; Biological and medical sciences ; Child ; CHILDREN ; Desensitization, Immunologic ; DOUBLE-BLIND ; Double-Blind Method ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; grass pollen ; HOUSE-DUST MITE ; Humans ; Immunopathology ; Immunotherapy ; Male ; Medical sciences ; PEDIATRIC-PATIENTS ; PLACEBO-CONTROLLED EVALUATION ; Poaceae - immunology ; Pollen - immunology ; primary care ; Primary Health Care ; QUALITY-OF-LIFE ; RANDOMIZED CONTROLLED-TRIAL ; Retrospective Studies ; RHINITIS ; Rhinitis, Allergic, Seasonal - immunology ; Rhinitis, Allergic, Seasonal - therapy ; SEASONAL ALLERGIC RHINOCONJUNCTIVITIS ; sublingual ; SWALLOW IMMUNOTHERAPY
    ISSN: 0091-6749
    E-ISSN: 1097-6825
    Source: Backfile Package - All of Back Files EBS [ALLOFBCKF]
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: Clinical cancer research, 2007-12-15, Vol.13 (24), p.7357-7362
    Description: Purpose: Magnetic resonance imaging (MRI) screening enables early detection of breast cancers in women with an inherited predisposition. Interval cancers occurred in women with a BRCA1 mutation, possibly due to fast tumor growth. We investigated the effect of a BRCA1 or BRCA2 mutation and age on the growth rate of breast cancers, as this may influence the optimal screening frequency. Experimental Design: We reviewed the invasive cancers from the United Kingdom, Dutch, and Canadian MRI screening trials for women at hereditary risk, measuring tumor size at diagnosis and on preceding MRI and/or mammography. We could assess tumor volume doubling time (DT) in 100 cancers. Results: Tumor DT was estimated for 43 women with a BRCA1 mutation, 16 women with a BRCA2 mutation, and 41 women at high risk without an identified mutation. Growth rate slowed continuously with increasing age ( P = 0.004). Growth was twice as fast in BRCA1 ( P = 0.003) or BRCA2 ( P = 0.03) patients as in high-risk patients of the same age. The mean DT for women with BRCA1/2 mutations diagnosed at ages ≤40, 41 to 50, and 〉50 years was 28, 68, and 81 days, respectively, and 83, 121, and 173 days, respectively, in the high-risk group. Pathologic tumor size decreased with increasing age ( P = 0.001). Median size was 15 mm for patients ages ≤40 years compared with 9 mm in older patients ( P = 0.003); tumors were largest in young women with BRCA1 mutations. Conclusion: Tumors grow quickly in women with BRCA1 mutations and in young women. Age and risk group should be taken into account in screening protocols.
    Subject(s): Adult ; Age Factors ; Antineoplastic agents ; Biological and medical sciences ; BRCA1 ; BRCA1, BRCA2 ; BRCA2 ; breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Canada ; cancer surveillance and screening ; Cell Proliferation ; familial and hereditary cancers ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Genetic Predisposition to Disease ; Gynecology. Andrology. Obstetrics ; Humans ; Magnetic Resonance Imaging ; magnetic resonance imaging (MRI) ; Mammary gland diseases ; Mass Screening ; Medical sciences ; Middle Aged ; Mutation ; Netherlands ; Pharmacology. Drug treatments ; screening ; tumor growth rate ; Tumors ; United Kingdom
    ISSN: 1078-0432
    E-ISSN: 1557-3265
    Source: HighWire Press (Free Journals)
    Source: Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Language: English
    In: Pediatric pulmonology, 2013-02, Vol.48 (2), p.130-137
    Description: Background Survival rates of patients with congenital diaphragmatic hernia (CDH) have improved to up to 80%. Little is known about long‐term consequences of the disease and its treatment. We evaluated lung function and respiratory symptoms longitudinally in a previously studied cohort of CDH patients and age‐matched non‐CDH patients who underwent similar neonatal intensive care treatment. Study Design We tested 27 young adults [mean (SD) age: 26.8 years (2.9)] with CDH and 30 non‐CDH patients. Dynamic and static lung volumes, midexpiratory flows, and diffusion capacity were expressed as mean (SD) standard deviation scores. Prevalence of respiratory symptoms was evaluated with the European Community Respiratory Health Survey. Results All data are expressed as mean (SD). FEF25–75 in CDH patients had slightly deteriorated since childhood (CDH: −0.7 (1.4) vs. −1.6 (1.5), P 〈 0.001; non‐CDH patients: 0.2 (1.4) vs. −0.3 (1.6), P = 0.038, ns). Diffusion capacity decreased in both groups (CDH: DLCOc 0.2 (1.1) vs. −1.5 (1.1), P 〈0.001; non‐CDH: DLCOc 0.1 (0.4) vs. −1.1 (1.1), P 〈 0.001). Lung volumes were normal in both groups. The prevalence of asthma was higher than in the normal population (27.6% in patients and 30% in controls, P 〈 0.001). Conclusions Airflow obstruction and diffusion capacity deteriorated mildly from childhood into adulthood in survivors of CDH. The improved survival of patients with more severe forms of diaphragmatic hernia calls for long‐term follow‐up of lung function. Pediatr Pulmonol. 2013; 48:130–137. © 2012 Wiley Periodicals, Inc.
    Subject(s): Adult ; Case-Control Studies ; Cohort Studies ; Disease Progression ; Female ; Hernia, Diaphragmatic - physiopathology ; Hernias, Diaphragmatic, Congenital ; Humans ; Longitudinal Studies ; Lung - physiopathology ; lung physiology ; Male ; mechanical ventilation ; pediatric lung disease ; Respiratory Function Tests ; respiratory measurement ; Young Adult
    ISSN: 8755-6863
    E-ISSN: 1099-0496
    Source: Hellenic Academic Libraries Link
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Pediatric Blood & Cancer, 2013-02, Vol.41 (2), p.258-261
    Description: Background Mesenchymal cells (MSCs) in bone marrow (BM) may produce asparagine and form protective niches for leukemic cells. In vitro, this led to high levels of asparagine and conferred asparaginase resistance to acute lymphoblastic leukemia (ALL) cells. The aim of this study was to investigate whether MSCs or other cells in BM indeed produce such significant amounts of asparagine in vivo as to result in clinical asparaginase resistance. Procedure Twenty‐six patients with newly diagnosed ALL were enrolled. All children received induction chemotherapy according to the Dutch Childhood Oncology Group (DCOG) ALL‐10 protocol. Asparaginase was administered from days 12–33. Asparaginase, asparagine, aspartic acid, glutamine, and glutamic acid levels were measured in BM and blood at diagnosis, days 15, 33, and 79. Results Median asparaginase trough levels were not significantly different at days 15 and 33. Only at diagnosis, asparagine level was significantly higher in BM than in blood (P = 0.001). Asparagine levels were all below the lower limit of quantification in BM and blood at days 15 and 33. However, aspartic acid level in BM was significantly higher than in blood (P 〈 0.001) at diagnosis, and also at days 15, 33, and 79. Conclusions We demonstrate higher aspartic acid levels in BM compared to blood; however, no increased asparagine levels were seen during induction therapy containing asparaginase in BM when compared to blood. Therefore, increased asparagine synthesis by MSCs is of relevance for resistance to asparaginase of leukemic cells in vitro, but it is questionable whether this leads to asparaginase resistance in childhood ALL patients. Pediatr Blood Cancer 2013;60:258–261. © 2012 Wiley Periodicals, Inc.
    Subject(s): Acute lymphocytic leukemia ; Adolescent ; Amino acids ; Analysis ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Asparaginase ; Asparaginase - therapeutic use ; asparagine ; Asparagine - analysis ; aspartic acid ; bone marrow ; Bone Marrow - chemistry ; Cancer ; Care and treatment ; Chemotherapy ; Child ; Child, Preschool ; childhood acute lymphoblastic leukemia ; Female ; Glutamate ; Humans ; Infant ; Male ; mesenchymal cells ; Oncology, Experimental ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism ; Research ; Stem cells
    ISSN: 0096-0802
    ISSN: 1545-5009
    ISSN: 1096-911X
    E-ISSN: 1096-911X
    E-ISSN: 1545-5017
    Source: Hellenic Academic Libraries Link
    Source: Wiley Online Library All Journals
    Source: Alma/SFX Local Collection
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: English
    In: Journal of allergy and clinical immunology, 2013, Vol.132 (2), p.482-485.e10
    Description: Byline: E. Marije Bakker (a), Els C. van der Wiel-Kooij (a), Bernhard Mullinger (b), Philipp Kroneberg (b), Wim C.J. Hop (c), Harm A.W.M. Tiddens (a) Author Affiliation: (a) Department of Pediatric Pulmonology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands (b) Activaero GmbH, Gemunden, Germany (c) Department of Biostatistics, Erasmus MC, Rotterdam, The Netherlands Article Note: (footnote) Supported by Roche Netherlands B.V., Stichting Vrienden van het Sophia (Friends of Sophia Children's Hospital Foundation), Stichting Astma Bestrijding (Dutch Fund for Asthma), and Activaero GmbH. Roche BV Netherlands supplied dornase alfa for use in this study free of charge., Disclosure of potential conflict of interest: E. M. Bakker has been supported by one or more grants from Stichting Astma Bestrijding. B. Mullinger is employed by, has one or more patents (planned, pending, or issued) with, and owns stock/stock options in Activaero. P. Kroneberg is employed by and has one or more patents (planned, pending, or issued) with Activaero. A. W. M. Tiddens has been supported by one or more grants from Roche Pharmaceuticals; has consultancy arrangements with Gilead, Novartis, Pharmaxis, Insmed, and Siemens; is employed by the University of Washington (Visiting Professorship [grant by CFF]) and by the University of Cincinnati (Visiting Professorship [grant by CFF]); has received one or more payments for lecturing from or is on the speakers' bureau for Roche, Gilead, and Novartis; and has a combined patent on specific targeting with DNase. The rest of the authors declare that they have no relevant conflicts of interest.
    Subject(s): Abridged Index Medicus ; Adolescent ; Airway Obstruction - drug therapy ; Airway Obstruction - physiopathology ; Allergy and Immunology ; Asthma - complications ; Asthma - drug therapy ; Asthma - physiopathology ; Asthma in children ; Biological and medical sciences ; Child ; Deoxyribonuclease I - metabolism ; Deoxyribonuclease I - therapeutic use ; Dornase alfa ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Male ; Maximal Midexpiratory Flow Rate ; Medical sciences ; Nebulizers and Vaporizers ; Recombinant Proteins - metabolism ; Recombinant Proteins - therapeutic use ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Treatment Outcome
    ISSN: 0091-6749
    E-ISSN: 1097-6825
    Source: Backfile Package - All of Back Files EBS [ALLOFBCKF]
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: Surgery, 2007, Vol.142 (5), p.695-698
    Description: Background Open mesh or non-mesh inguinal hernia repair may influence the incidence of chronic postoperative pain differently. Methods A total of 300 patients scheduled for repair of a primary unilateral inguinal hernia were randomized to non-mesh or mesh repair. The primary outcome measure was clinical outcome including persistent pain and discomfort interfering with daily activity. Long-term results at 3 years of follow-up have been published. Included here are 10-year follow-up results with respect to pain. Results Of the 300 patients, 87 patients (30%) died and 49 patients (17%) were lost to follow-up. A total of 153 were physically examined in the outpatient clinic after a median long-term follow-up of 129 months (range, 109 to 148 months). None of the patients in the non-mesh or mesh group suffered from persistent pain and discomfort interfering with daily activity. Conclusions Our 10-year follow-up study provides evidence that mesh repair of inguinal hernia is equal to non-mesh repair with respect to long-term persistent pain and discomfort interfering with daily activity. An important new finding from the patient’s perspective is that chronic postoperative pain seems to dissipate over time.
    Subject(s): Abridged Index Medicus ; Activities of Daily Living ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Chronic Disease ; Clinical trials ; Female ; Follow-Up Studies ; General aspects ; Hernia, Inguinal - surgery ; Humans ; Inguinal hernia ; Male ; Medical sciences ; Middle Aged ; Pain, Postoperative ; Patient Satisfaction ; Surgery ; Surgical Mesh ; Time Factors ; Treatment Outcome
    ISSN: 0039-6060
    E-ISSN: 1532-7361
    Source: Alma/SFX Local Collection
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: English
    In: Haematologica (Roma), 2010-05-01, Vol.95 (5), p.752-759
    Description: Background This study investigates pharmacogenetic risk factors for bone mineral (apparent) density (BM(A)D) and body composition in pediatric acute lymphoblastic leukemia Design and Methods We determined the influence of SNPs in 4 genes (vitamin-D receptor (VDR: BsmI/ApaI/TaqI and Cdx-2/GATA), collagen type I alpha 1 (SpI), estrogen receptor 1 (ESR1: PvuII/XbaI), glucocorticoid receptor (BclI)) on body composition, BM(A)D and fracture risk during dexamethasone-based pediatric acute lymphoblastic leukemia treatment. Body composition and BMD were measured repeatedly during and after treatment using dual energy X-ray absorptiometry. Results Non-carriers of VDR 5'-end (Cdx-2/GATA) haplotype 3 revealed a significant larger fat gain than carriers (D%fat: non-carriers: +1.76SDS, carriers: +0.77SDS, P〈0.001). At diagnosis and during therapy, lumbar spine BMD was significantly higher in non-carriers of VDR 5'-end (Cdx-2/GATA) haplotype 3 than in carriers. The other SNPs did not influence BMD or fracture risk during/after treatment. The year after treatment completion, lean body mass increased in non-carriers of ESR1 (PvuII/XbaI) haplotype 3 and decreased in carriers (D lean body mass: non-car-riers:+0.28SDS, carriers: -0.55SDS, P〈0.01). Conclusions Only VDR 5'-end (Cdx-2/GATA) haplotype 3 was identified as protective factor against excessive fat gain and as a risk factor for lower lumbar spine BMD during treatment. Carrying ESR1 (PvuII/XbaI) haplotype 3 negatively influenced recovery of lean body mass after pediatric acute lymphoblastic leukemia treatment.
    Subject(s): Acute lymphoblastic leukemia ; Adolescent ; Biological and medical sciences ; Body Composition - drug effects ; Body Composition - genetics ; Bone Density - drug effects ; Bone Density - genetics ; Cdx-2 ; Cdx-2/GATA ; Child ; Child, Preschool ; Cohort Studies ; Dexamethasone - adverse effects ; Estrogen Receptor alpha - genetics ; Female ; Follow-Up Studies ; GATA ; Genetic Variation - genetics ; Hematologic and hematopoietic diseases ; Humans ; Infant ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Original ; Pharmacogenetic risk factors ; Polymorphism, Single Nucleotide - genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics ; Prospective Studies ; Receptors, Calcitriol - genetics ; Risk Factors
    ISSN: 0390-6078
    E-ISSN: 1592-8721
    Source: HighWire Press (Free Journals)
    Source: PubMed Central
    Source: DOAJ Directory of Open Access Journals - Not for CDI Discovery
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...